

Serial No.: 09/890,387
Group Art Unit No.: 3728

AMENDMENTS TO THE SPECIFICATION

Please amend the specification, as follows:

At page 1, line 6:

This invention relates to containers and in particular to containers with plastics material walls whose contents can undesirably permeate through the container walls or which are sensitive to ingress of material through the container walls. In particularly particular, the invention relates to such containers when used for medicaments.

16
At page 4, lines 24 and 27:

The container of the invention is suitable for a wide variety of medicament contents, particularly fluids such as liquid, gel, cream or paste medicaments i.e. which incorporate a solvent vehicle. Such medicaments may for example be suitable for topical applications or for applications to selected parts of the body e.g. a nasal medicament. Such medicaments may be applied as a spray, droplet or surface smear to such a selected part of the body. Examples of such medicaments are liquid formulations based on known pharmaceutically acceptable oily vehicles such as monoglycerides, ~~such as~~ for example, mono-olein and mono-linolein, phospholipids such as phosphatidyl cholines, and galactolipids such as glyceryl diglycerides. Typically such monoglycerides may be long-chain fatty acid monoglycerides, optionally also containing a long-chain ~~diglyceride~~ diglyceride. Such mono- and di- glycerides may for example be blends of different long-chain fatty acid mono- and di- glycerides. Examples of such fatty acid monoglycerides include glycerol mono-oleate, glycerol monopalmitate and glycerol monostearate. Suitable commercially available examples of such products include those available under the trade names MYVEROL, such as MYVEROL, MYVATEX, MYVAPLEX and GMORPHIC 80 respectively. Another example of such a material is ARLACEL 186, which in addition to glycerol mono-oleate includes propylene glycol. Typically in such long-chain monoglycerides the major fatty acid component is a C₁₈ saturated, mono-unsaturated or polyunsaturated fatty acid. Such oily vehicle based medicaments may also include fatty acid triglycerides, typically a vegetable oil, for example as diluents with the above-mentioned fatty acid monoglycerides. Examples of such include coconut oil, e.g. fractionated coconut oil. Commercially available examples of such triglyceride diluent materials include caprylic / capric triglyceride (Tricaprylin). Examples of such materials which are commercially available include those available under the trade names MYRITOL, CAPTEX and MIGLYOL. Examples of such oily vehicles are for example disclosed in WO98/14189A (SmithKline Beecham PLC) the contents of which are included herein by way of reference. The container of the invention is suitable for use with a wide range of active compounds dissolved or dispersed in such a vehicle. A particular example of such an active

Serial No.: 09/890,387
Group Art Unit No.: 3728

B3
Initialled

compound is the compound the antibiotic Mupirocin (Pseudomonic acid, "BactrobanTM") typically in the form of calcium mupirocin. An example of such a mupirocin formulation suitable for use as a nasopharyngeal spray formulation is also disclosed in WO98/14189A, typically comprising fractionated coconut oil (i.e. medium chain length triglycerides) e.g. the commercial product MIGLYOL, glycerol mono-oleate e.g. the commercial product MYVEROL 18-99, powdered lemon juice flavour, and micronised calcium mupirocin. The container of the invention is for example provided for, or containing, such a formulation.
